Skip to content
OpenCapital
Get started

Icahn Enterprises IEP Pharma — Net Sales

Other segment segments

Energy
$1.98B+20.3%
Automotive
$187M-5.6%
Food Packaging
$87M-7.4%
Home Fashion
$39M-4.9%

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$4.9B+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by Icahn Enterprises in its filing.

Tagged under the XBRL concept iep:NetSales.

The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Icahn Enterprises's pharma — net sales.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Icahn Enterprises's pharma — net sales?
Icahn Enterprises (IEP) reported pharma — net sales of $15M in Q1 2026.
How has Icahn Enterprises's pharma — net sales changed year-over-year?
Icahn Enterprises's pharma — net sales decreased by 34.8% year-over-year, from $23M to $15M.
What is the long-term trend for Icahn Enterprises's pharma — net sales?
Over 4 years (2021 to 2025), Icahn Enterprises's pharma — net sales has grown at a 5.1% compound annual growth rate (CAGR), from $81M to $99M.
What does pharma — net sales mean?
The total revenue generated from the sale of pharmaceutical products, net of returns, allowances, and discounts. This is the primary measure of the segment's core commercial performance and market demand for its therapeutic portfolio.